89 related articles for article (PubMed ID: 26988273)
1. YKL-40 protein in osteosarcoma tumor tissue.
Thorn AP; Daugaard S; Christensen LH; Christensen IJ; Petersen MM
APMIS; 2016 Jun; 124(6):453-61. PubMed ID: 26988273
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.
Dumars C; Ngyuen JM; Gaultier A; Lanel R; Corradini N; Gouin F; Heymann D; Heymann MF
Oncotarget; 2016 Nov; 7(48):78343-78354. PubMed ID: 27823976
[TBL] [Abstract][Full Text] [Related]
3. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors.
Harving ML; Christensen LH; Ringsholt M; Lausten GS; Petersen MM
Acta Orthop; 2014 Apr; 85(2):195-200. PubMed ID: 24650028
[TBL] [Abstract][Full Text] [Related]
5. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD163, interleukin-10, and interferon-gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications.
Wang S; Sun M; Gu C; Wang X; Chen D; Zhao E; Jiao X; Zheng J
Eur J Oral Sci; 2014 Jun; 122(3):202-9. PubMed ID: 24796206
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.
Bi J; Lau SH; Lv ZL; Xie D; Li W; Lai YR; Zhong JM; Wu HQ; Su Q; He YL; Zhan WH; Wen JM; Guan XY
Hum Pathol; 2009 Dec; 40(12):1790-7. PubMed ID: 19765801
[TBL] [Abstract][Full Text] [Related]
9. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
11. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.
Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P
Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance.
Fujii N; Shomori K; Shiomi T; Nakabayashi M; Takeda C; Ryoke K; Ito H
J Oral Pathol Med; 2012 Jul; 41(6):444-51. PubMed ID: 22296275
[TBL] [Abstract][Full Text] [Related]
13. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer.
Vom Dorp F; Tschirdewahn S; Niedworok C; Reis H; Krause H; Kempkensteffen C; Busch J; Kramer G; Shariat SF; Nyirady P; Rübben H; Szarvas T
J Urol; 2016 Apr; 195(4 Pt 1):1120-5. PubMed ID: 26454102
[TBL] [Abstract][Full Text] [Related]
14. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
15. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
17. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
18. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
19. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN.
Zhao L; David MZ; Hyjek E; Chang A; Meehan SM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):54-62. PubMed ID: 25516918
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.
Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL
Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
